Skip to main content

Table 1 Blood pressure and basic biochemistry at baseline and after the 28-day treatment with fenofibrate or placebo

From: Treatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox status

Parameter Baseline After Placebo After Fenofibrate
Systolic blood pressure [mmHg] 138 ± 17 137 ± 12 134 ± 11
Diastolic blood pressure [mmHg] 91 ± 22 92 ± 18 93 ± 23
S-sodium [mmol/L] 139 ± 3 137 ± 3* 138 ± 3
S-potassium [mmol/L] 5.1 ± 0.9 5.1 ± 0.8 5.2 ± 0.8
S-albumin [g/L] 37.9 ± 3.4 38.4 ± 2.8 38.3 ± 3.3
S-urea [mg/dL] 128.2 ± 36.0 134.0 ± 28.1 139.1 ± 28.9
S-creatinine [mg/dl] 8.7 ± 2.4 8.8 ± 2.3 8.8 ± 2.3
S-GOT [IU/L] 21.1 ± 12.8 22.6 ± 9.1 23.3 ± 22.6
S-Creatine kinase [IU] 78.9 ± 48.8 72.9 ± 49.7 95.3 ± 63.9#
S-CRP [mg/L] 6.4 ± 5.2 7.2 ± 7.6 7.9 ± 9.1
  1. # p = 0.01 vs baseline; * p < 0.05 vs baseline